Certolizumab pegol (Cimzia) for rheumatoid arthritis - horizon scanning review
NHSC
Record ID 32005001215
English
Authors' objectives:
This study aims to summarise the currently available evidence on Certolizumab pegol (Cimzia) for rheumatoid arthritis.
Authors' recommendations:
Certolizumab pegol (Cimzia) is a subcutaneous anti-tumour necrosis factor (TNF)-alpha monoclonal antibody, currently in phase III trials for the treatment of rheumatoid arthritis (RA) in patients who had previously received at least one disease modifying antirheumatic drug (DMARD) therapy. Positive results from an unpublished phase III study of certolizumab pegol monotherapy have been reported by the company. A double-blind, randomised, placebo-controlled, phase II study in 204 patients with active rheumatoid arthritis showed an improvement of 16% to 77% compared with 12% to 33% for placebo.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Tumor Necrosis Factor-alpha
- Arthritis, Rheumatoid
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.